20 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Prostatic Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Conditions: Prostate Cancer;   Sexual Dysfunction and Infertility;   Sexuality
Interventions: Other: communication intervention;   Other: counseling intervention;   Other: nutrition intervention;   Other: questionnaire administration
2 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: hydroxychloroquine;   Other: pharmacological study;   Other: laboratory biomarker analysis
3 Recruiting Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
4 Recruiting Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy;   Drug: docetaxel
5 Recruiting Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Abiraterone;   Drug: ABT-263;   Drug: Hydroxychloroquine
6 Recruiting 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate;   Drug: Abiraterone acetate plus degarelix;   Drug: Degarelix
7 Recruiting Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: docetaxel;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Procedure: conventional surgery
8 Recruiting Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Procedure: therapeutic dietary intervention
9 Recruiting Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Biological: ipilimumab;   Other: laboratory biomarker analysis
10 Recruiting Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: prednisone;   Drug: veliparib;   Other: laboratory biomarker analysis
11 Recruiting LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: bicalutamide;   Procedure: orchiectomy;   Drug: leuprolide acetate;   Drug: goserelin acetate;   Other: laboratory biomarker analysis
12 Recruiting Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
Conditions: Prostate Cancer;   Prostatic Neoplasms
Interventions: Drug: Panobinostat;   Drug: Bicalutamide
13 Recruiting Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
14 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
15 Recruiting Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Muscadine Plus Grape Skin Extract
16 Recruiting Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Tesetaxel
17 Recruiting A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V;   Biological: PROSTVAC-F;   Drug: GM-CSF;   Other: GM-CSF Placebo;   Biological: Placebo
18 Unknown  DNA Changes in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
19 Unknown  PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802
Condition: Prostate Cancer
Intervention: Other: laboratory biomarker analysis
20 Recruiting Molecular Studies and Clinical Correlations in Human Prostatic Disease
Condition: Prostate Cancer
Intervention:

Indicates status has not been verified in more than two years